Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors (PD-1 & PD-L1 Targeting Drugs): Analysis of Clinical Trial Results (Featuring Insightful Summaries of Recently Published Trial Results, Contemporary Pipeline Review, Clinical Trial Analysis, Clinical Publications Analysis, and Estimated Time to Market Analysis for Novel Drug Candidates)

  • Lowest Price Guaranteed From USD 1,299

  • Companies Covered
    0

  • Slides
    84

  • View Count
    8648

Table Of Contents

Excel Deliverable
1.Summary Dashboard

1.1. Pipeline Review
1.2. Clinical Trials Analysis
1.3. Analysis of Clinical Trial Results-related Publications
1.4. Analysis of Clinical Trial Results-related Publications, 2020-2021
1.5. Estimated Time to Launch Analysis

2. Contemporary Product Pipeline Dataset

3. Clinical Trials Dataset

4. Clinical Trial Results-related Publications Dataset

5. Clinical Trial Results Analysis Dataset

6. Estimated Time to Launch Dataset

7. Appendices

PowerPoint Deliverable
1. Context

2. Project Approach

3. Project Objectives

Section I

4. Executive Summary

Section II
5. Analysis of Clinical Trial Results

5.1. Overview
5.2. Scope and Methodology
5.3. PD-1 & PD-L1 Inhibitors: Phase I Trials
5.4. PD-1 & PD-L1 Inhibitors: Phase II Trials
5.5. PD-1 & PD-L1 Inhibitors: Phase III Trials
5.6. Concluding Remarks

Section III
6. Contemporary Product Pipeline Dataset

6.1. Overview
6.2. PD-1 & PD-L1 Inhibitors Pipeline
6.2.1. Analysis by Biological Target
6.2.2. Analysis by Type of Molecule
6.2.3. Analysis by Phase of Development
6.2.4. Analysis by Mechanism of Action
6.3. PD-1 & PD-L1 Inhibitors: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. Concluding Remarks

Section IV
7. Clinical Trials Analysis

7.1. Overview
7.2. PD-1 & PD-L1 Inhibitors: Clinical Trials
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Phase
7.2.3. Analysis by Enrolled Patient Population
7.3.4. Analysis by Study Design
7.3.5. Analysis by Sponsor / Collaborator
7.3.6. Most Active Industry Players: Analysis by Number of Registered Trials
7.3.7. Most Active Non-Industry Players: Analysis by Number of Registered Trials
7.3.8. Analysis by Target Therapeutic Area
7.3.9. Geographical Analysis by Number of Registered Trials
7.3.10. Geographical Analysis by Enrolled Patient Population

Section V
8. Clinical Trial Results-related Publications Dataset

8.1. Overview
8.2. Scope and Methodology
8.3. PD-1 & PD-L1 Inhibitors: List of Clinical Trial-related Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Biological Target
8.3.3. Analysis by Target Therapeutic Area
8.3.4. Key Journals: Analysis by Number of Publications
8.3.5. Key Journals: Analysis by Impact Factor
8.3.6. Most Popular First Authors: Analysis by Number of Publications
8.4. Concluding Remarks

Section VI
9. Estimated Time to Launch

9.1. Overview
9.2. Scope and Methodology
9.3. PD-1 & PD-L1 Inhibitors: Estimated Time to Launch for Novel Drug Candidates
9.4. Concluding Remarks

Section VII
10. Conclusion

Section VIII
11. Appendices I: Tabulated Data

12. Appendices II: List of Companies & Organizations

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 4-Antibody AG
  2. Abbott
  3. AbbVie
  4. AbClon
  5. Abeome
  6. ABL Bio
  7. Abpro
  8. Acerta Pharma
  9. Acrus Biosciences
  10. Actinium Pharmaceuticals
  11. Adaptive Biotechnologies
  12. Adimab
  13. AdoRx Therapeutics
  14. Aduro Biotech
  15. Advaxis
  16. Agenus
  17. Agios Pharmaceuticals
  18. AgonOX
  19. Alexion Pharmaceuticals
  20. Allergan
  21. Alligator Bioscience 
  22. Alpine Immune Sciences
  23. ALX Oncology
  24. Ambrx
  25. American Society of Clinical Oncology
  26. Amgen
  27. Amplimmune
  28. AnaptysBio
  29. Angel Therapeutics
  30. Anvil Biosciences (The company has been acquired)
  31. Apexigen
  32. Apogenix
  33. Aptevo Therapeutics
  34. Arch Oncology
  35. Arcus Biosciences
  36. arGEN-X
  37. ArQule
  38. Astellas Pharma
  39. Astex Pharmaceuticals
  40. AstraZeneca
  41. Atridia
  42. Aurigene
  43. Aurigene Discovery Technologies
  44. Avacta Life Sciences
  45. Azienda Ospedaliera Universitaria Senese
  46. Bach BioSciences
  47. Bayer
  48. BeiGene
  49. BinDeBio Group
  50. BIOCAD
  51. Biodextris
  52. Bio-Matrix Scientific Group
  53. BioNTech
  54. Bio-Techne
  55. BioWa
  56. Black Belt Therapeutics
  57. BliNK Biomedical
  58. bluebird bio
  59. Boehringer Ingelheim
  60. Boston Medical Center 
  61. Brigham and Women's Hospital
  62. Bristol Myers Squibb
  63. Bristol-Myers Squibb
  64. Calithera Biosciences
  65. CALIXAR
  66. Canadian Cancer Trials Group
  67. CASI Pharmaceuticals
  68. Catalent Biologics
  69. Celgene
  70. Cell Genesys 
  71. Celldex Therapeutics
  72. Center for Applied Medical Research 
  73. Centre Georges Francois Leclerc
  74. Centro Nacional de Investigaciones Oncologicas CARLOS III
  75. Centrose
  76. Changhai Hospital
  77. Checkpoint Therapeutics
  78. China National Biotec Group
  79. City of Hope Medical Center
  80. CleveXel Pharma
  81. Clinical Research Institute 
  82. Columbia University
  83. Columbia University Irving Medical Center
  84. Compass Therapeutics
  85. Compugen
  86. Corvus Pharmaceuticals
  87. CoStim Pharmaceuticals
  88. Crescendo Biologics
  89. CStone Pharmaceuticals
  90. CureTech
  91. Curis
  92. D5Pharma
  93. Daiichi Sankyo
  94. Dana-Farber Cancer Institute
  95. Distributed Bio
  96. DNAtrix
  97. Domain Therapeutics
  98. Dova Pharmaceuticals
  99. Dualogics
  100. Eddingpharm
  101. Eisai
  102. Eli Lilly
  103. Elpiscience Biopharma
  104. ELSALYS BIOTECH
  105. EMulate Therapeutics
  106. EpicentRx
  107. European Thoracic Oncology Platform
  108. Facet Biotech
  109. FF Pharmaceuticals
  110. Five Prime Therapeutics
  111. Fondazione IRCCS Istituto Nazionale dei Tumori
  112. Forty Seven
  113. Fred Hutchinson Cancer Research Center
  114. F-star
  115. Gateway Biologics
  116. Genentech
  117. Genmab
  118. Genomics Medicine Ireland
  119. Genosco
  120. Georgia Health Sciences University
  121. GERCOR - Multidisciplinary Oncology Cooperative Group
  122. GigaGen
  123. Gilead Sciences
  124. Glaxosmithkline
  125. Glenmark
  126. Glycotope 
  127. Grupo Espanol de Investigacion en Sarcomas
  128. Gustave Roussy Institute 
  129. Hanmi Pharmaceutical
  130. HanX Biopharmaceuticals 
  131. HealthCare Ventures
  132. Heat Biologics
  133. Hoffmann-La Roche
  134. Hospices Civils de Lyon
  135. Hrain Biotechnology
  136. Hummingbird Bioscience
  137. IDM
  138. IGM Biosciences
  139. I-Mab Biopharma
  140. Immatics
  141. ImmuneOncia Therapeutics
  142. ImmuneOnco Biopharmaceuticals
  143. ImmuNext
  144. Immutep
  145. Imperial College London
  146. Impetis Biosciences 
  147. Incyte
  148. Inhibrx
  149. Innate Pharma
  150. Innovent Biologics
  151. Institute for Research in Biomedicine
  152. InteRNA Technologies
  153. International Myeloma Foundation
  154. IO Biotech
  155. iOnctura
  156. iTeos Therapeutics
  157. Janssen Pharmaceuticals
  158. Jiangsu HengRui Medicine
  159. Jiangxi Qingfeng Pharmaceutical
  160. JN Biosciences
  161. Johns Hopkins University
  162. Johnson & Johnson
  163. Jounce Therapeutics
  164. Juventas Cell Therapy
  165. KAHR Medical
  166. Kiniksa Pharmaceuticals
  167. Kite Pharma
  168. Kleo Pharmaceuticals
  169. Kymab
  170. Kyowa Hakko Kirin
  171. Lankenau Institute for Medical Research (LIMR)
  172. Laureate Pharma
  173. Leap Therapeutics
  174. Lee's Pharma 
  175. LG Chem
  176. LifeArc
  177. Lonza Biologics
  178. Ludwig Cancer Research
  179. Lynkcell 
  180. M.D. Anderson Cancer Center
  181. Macrocure
  182. MacroGenics 
  183. Marino Biotechnology
  184. Masonic Cancer Center
  185. Massachusetts General Hospital
  186. Medarex
  187. MedImmune
  188. Medivation
  189. Merck 
  190. Merck KGaA
  191. Merck Serono
  192. Merck Sharp & Dohme
  193. Merus
  194. Millennium Pharmaceuticals
  195. Moderna
  196. Molecular Partners
  197. MolMed
  198. Momenta Pharmaceuticals
  199. Morphiex
  200. MorphoSys
  201. Mount Sinai Innovation Partners
  202. MRC Technology
  203. Nanjing Chia Tai Tianqing
  204. National Cancer Center Hospital East
  205. National Cancer Institute
  206. National Heart, Lung, and Blood Institute
  207. National Institute of Allergy and Infectious Diseases
  208. National Institute of Biomedical Imaging and Bioengineering
  209. National Institute of Dental and Craniofacial Research
  210. National Institute of Diabetes and Digestive and Kidney Diseases
  211. National Institute of Neurological Disorders
  212. NavarraBiomed-Biomedical Research Centre
  213. Navigen
  214. Nektar Therapeutics
  215. Neon Therapeutics
  216. NewLink Genetics
  217. NextCure
  218. Northwestern University
  219. Novartis
  220. Novartis Pharmaceuticals
  221. Novimmune
  222. Novo Nordisk
  223. Numab Therapeutics
  224. Ogeda
  225. OncoArendi Therapeutics 
  226. Oncotelic
  227. Oncothyreon
  228. Ono Pharmaceutical
  229. Onyx (subsidiary of Amgen) 
  230. Orega Biotech
  231. ORIC Pharmaceuticals
  232. OSE Immunotherapeutics
  233. Oslo University Hospital
  234. Palobiofarma
  235. Pandion Therapeutics
  236. Paradigm Shift Therapeutics
  237. Parker Institute for Cancer Immunotherapy
  238. Pascal Biosciences
  239. PDL Biopharma
  240. Peking University
  241. Peking University People's Hospital
  242. Peloton Therapeutics
  243. PeptiDream
  244. PersonGen BioTherapeutics (Suzhou) 
  245. Pfizer
  246. PharmAbcine
  247. Pieris Pharmaceuticals
  248. Pierre Fabre
  249. Pinze Lifetechnology
  250. Polaris Group
  251. Potenza Therapeutics
  252. Prima BioMed 
  253. PsiOxus Therapeutics
  254. Recipharm Cobra Biologics
  255. Regeneron Pharmaceuticals
  256. Regis Technologies 
  257. Roche
  258. Royal Marsden NHS Foundation Trust
  259. Rubius Therapeutics
  260. Samsung Biologics
  261. Samsung Medical Center
  262. Sanofi
  263. Sanquin
  264. Seattle Genetics
  265. Servier
  266. Shanghai GeneChem
  267. Shanghai Junshi Bioscience
  268. Shattuck Labs
  269. Shire
  270. Sorrento Therapeutics
  271. Spring Bioscience
  272. Stanford University
  273. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  274. Surface Oncology
  275. Sutro Biopharma
  276. Swedish Orphan Biovitrum
  277. Symphogen
  278. Synthon International Holding
  279. Syros Pharmaceuticals
  280. Taizhou Hanzhong biomedical
  281. Takeda Pharmaceutical
  282. Tarus Therapeutics 
  283. Tempest Therapeutics
  284. TESARO
  285. TG Therapeutics
  286. The First Affiliated Hospital with Nanjing Medical University
  287. The National Cancer Institute, Mexico
  288. The Netherlands Cancer Institute
  289. The University of Texas MD Anderson Cancer Center
  290. Tianjin Medical University Cancer Institute and Hospital
  291. ToleroTech
  292. Tottori University
  293. TRACON Pharmaceuticals
  294. Trellis Biosciences
  295. TRIGR Therapeutics
  296. Trillium Therapeutics
  297. Tsinghua University
  298. Union Stem Cell & Gene Engineering
  299. University Health Network, Toronto
  300. University Medical Center Hamburg-Eppendorf
  301. University of Birmingham
  302. University of California, Berkeley
  303. University of California, Los Angeles
  304. University of California, San Diego
  305. University of California, San Francisco
  306. University of Cologne
  307. University of Iowa Pharmaceutical Services
  308. University of Louisville
  309. University of Minnesota 
  310. University of Texas 
  311. Vall d’Hebron Institute of Oncology
  312. Valo Therapeutics
  313. Ventana Medical Systems
  314. Viela Bio
  315. ViraTherapeutics 
  316. Vivoryon Therapeutics
  317. Washington University
  318. Waterstone Hanxbio 
  319. Weill Medical College of Cornell University
  320. Xencor
  321. XOMA
  322. Yale Cancer Center
  323. Yale University
  324. Y-Biologics
  325. Y-mAbs Therapeutics
  326. Yuhan Pharmaceuticals
  327. Zai Lab
  328. Zymeworks

Source: acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21660

PRICING DETAILS

USD 1,299

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com